Stephens Investment Management Group LLC Purchases 10,868 Shares of Pacira Biosciences Inc (NASDAQ:PCRX)

Stephens Investment Management Group LLC grew its position in shares of Pacira Biosciences Inc (NASDAQ:PCRX) by 0.9% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,210,605 shares of the company’s stock after purchasing an additional 10,868 shares during the quarter. Stephens Investment Management Group LLC owned about 2.93% of Pacira Biosciences worth $52,649,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Frontier Capital Management Co. LLC bought a new position in Pacira Biosciences during the 1st quarter worth approximately $52,509,000. Baillie Gifford & Co. raised its holdings in Pacira Biosciences by 6.1% during the 1st quarter. Baillie Gifford & Co. now owns 990,908 shares of the company’s stock worth $37,715,000 after purchasing an additional 57,367 shares during the last quarter. Elk Creek Partners LLC raised its holdings in Pacira Biosciences by 5.3% during the 1st quarter. Elk Creek Partners LLC now owns 564,576 shares of the company’s stock worth $21,488,000 after purchasing an additional 28,382 shares during the last quarter. Geode Capital Management LLC raised its holdings in Pacira Biosciences by 7.4% during the 4th quarter. Geode Capital Management LLC now owns 516,774 shares of the company’s stock worth $22,231,000 after purchasing an additional 35,635 shares during the last quarter. Finally, Rice Hall James & Associates LLC raised its holdings in Pacira Biosciences by 2.7% during the 1st quarter. Rice Hall James & Associates LLC now owns 464,040 shares of the company’s stock worth $17,661,000 after purchasing an additional 12,213 shares during the last quarter. Hedge funds and other institutional investors own 99.89% of the company’s stock.

PCRX traded up $0.22 during mid-day trading on Thursday, reaching $39.42. 576,516 shares of the stock were exchanged, compared to its average volume of 585,952. The company has a debt-to-equity ratio of 0.99, a current ratio of 8.62 and a quick ratio of 7.83. The stock has a market capitalization of $1.68 billion, a PE ratio of 135.93, a PEG ratio of 1.56 and a beta of 1.15. The business has a 50 day moving average of $42.40. Pacira Biosciences Inc has a 1 year low of $35.07 and a 1 year high of $55.00.

Pacira Biosciences (NASDAQ:PCRX) last posted its quarterly earnings data on Thursday, August 8th. The company reported $0.41 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.14 by $0.27. The firm had revenue of $102.60 million for the quarter, compared to the consensus estimate of $99.92 million. Pacira Biosciences had a net margin of 2.04% and a return on equity of 8.79%. The business’s revenue for the quarter was up 22.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.24 EPS. On average, equities research analysts expect that Pacira Biosciences Inc will post 0.76 earnings per share for the current fiscal year.

Several research firms have recently weighed in on PCRX. Stifel Nicolaus set a $42.00 price objective on shares of Pacira Biosciences and gave the company a “hold” rating in a research note on Friday, August 9th. Barclays began coverage on shares of Pacira Biosciences in a research note on Tuesday, June 11th. They issued an “overweight” rating and a $52.00 price objective for the company. Zacks Investment Research upgraded shares of Pacira Biosciences from a “sell” rating to a “hold” rating and set a $47.00 price objective for the company in a research note on Friday, August 2nd. Wedbush set a $85.00 price objective on shares of Pacira Biosciences and gave the company a “buy” rating in a research note on Friday, June 28th. Finally, Mizuho upgraded shares of Pacira Biosciences from an “underperform” rating to a “neutral” rating and lifted their price objective for the company from $29.00 to $38.00 in a research note on Monday, May 6th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and eight have given a buy rating to the company’s stock. Pacira Biosciences has an average rating of “Hold” and a consensus price target of $54.13.

In other Pacira Biosciences news, VP Lauren Bullaro Riker sold 967 shares of Pacira Biosciences stock in a transaction on Tuesday, June 4th. The shares were sold at an average price of $42.91, for a total transaction of $41,493.97. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO David M. Stack sold 13,115 shares of Pacira Biosciences stock in a transaction on Monday, July 8th. The stock was sold at an average price of $42.88, for a total transaction of $562,371.20. The disclosure for this sale can be found here. Insiders have sold a total of 57,990 shares of company stock worth $2,497,045 over the last ninety days. Insiders own 5.80% of the company’s stock.

Pacira Biosciences Company Profile

Pacira BioSciences, Inc provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure.

Read More: Price Target

Institutional Ownership by Quarter for Pacira Biosciences (NASDAQ:PCRX)

Receive News & Ratings for Pacira Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.